Home/Pipeline/OraQuick® HIV Self-Test

OraQuick® HIV Self-Test

HIV

CommercialFDA Approved; Marketed

Key Facts

Indication
HIV
Phase
Commercial
Status
FDA Approved; Marketed
Companies

About OraSure

OraSure Technologies (OSUR) is a mission-driven diagnostics company focused on decentralizing healthcare through a portfolio of non-invasive testing and sample collection platforms. Its strategy has been built on internal innovation and strategic acquisitions, including DNA Genotek (sample management), BioMedomics (point-of-care rapid tests), and Sherlock Biosciences (next-gen molecular platforms). This has created a comprehensive ecosystem from sample to result, targeting infectious diseases, genetic conditions, and research applications. The company aims to improve healthcare access, quality, and value by empowering individuals and providers with actionable diagnostic insights.

View full company profile

About OraSure Technologies

OraSure Technologies' mission is to empower individuals and healthcare providers with rapid, accurate, and accessible diagnostic information. The company has achieved market leadership in oral fluid diagnostics, most notably with its FDA-approved OraQuick® tests for HIV and HCV, and its InteliSwab® COVID-19 test. Its strategy focuses on expanding its rapid test portfolio, growing its molecular collection business, and leveraging its platforms into new disease areas and geographic markets to drive sustainable growth beyond pandemic-related revenue.

View full company profile

Other HIV Drugs

DrugCompanyPhase
Vaxine HIV VaccineVaxinePreclinical
Tenofovir Disoproxil FumarateHeteroCommercial
NanoDDIContinuity BiosciencesPre-clinical
HIV Gene TherapyNanitePre-clinical
RGFields for HIVAnapole TechnologiesClinical (phase unspecified)
HIV mAb ProgramAdnexusPre-clinical
Undisclosed ProgramEnnoDCPhase 1
O2-16 SeriesOyaGenPreclinical
SBX 2048Stramsen BiotechEarly-stage Clinical
ALF PlatformSenzoPre-clinical
Gilead HIV FranchiseRoyalty PharmaMarketed
ANKTIVA-based regimensImmunityBioPhase 1/2